Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

24.44
-0.7900-3.13%
Post-market: 24.540.1000+0.41%19:30 EDT
Volume:1.04M
Turnover:25.52M
Market Cap:3.11B
PE:-6.32
High:25.58
Open:25.48
Low:24.09
Close:25.23
52wk High:31.74
52wk Low:13.21
Shares:127.33M
Float Shares:89.84M
Volume Ratio:0.75
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:6.71
PE(LYR):-7.43

Loading ...

Arcus Q1 net loss widens to $128 million; revenue falls to $17 million

Reuters
·
May 06

BRIEF-Arcus Biosciences Q1 Net Income USD -128 Million

Reuters
·
May 06

Arcus Biosciences Q1 Revenue USD 17 Million VS. Ibes Estimate USD 29.5 Million

THOMSON REUTERS
·
May 06

Arcus Biosciences Q1 Pretax Profit USD -128 Million

THOMSON REUTERS
·
May 06

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Simply Wall St.
·
May 04

Earning Preview: Arcus Biosciences Inc. this quarter’s revenue is expected to decrease by 19.31%, and institutional views are bullish

Earnings Agent
·
Apr 28

Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes

Simply Wall St.
·
Apr 27

Arcus Biosciences grants new hire options for 4,200 shares, RSUs for 2,100 shares

Reuters
·
Apr 25

Arcus Biosciences rises 12.2%

TIPRANKS
·
Apr 22

Arcus Biosciences schedules conference call on quarterly results, pipeline update

Reuters
·
Apr 22

Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

MT Newswires Live
·
Apr 22

Merck setback has positives and negatives for Arcus Biosciences, says BofA

TIPRANKS
·
Apr 22

Merck study miss not a read for Arcus, says H.C. Wainwright

TIPRANKS
·
Apr 22

Analysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
Apr 21

Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Arcus Biosciences Discontinues Lung Cancer Trial With Gilead

Dow Jones
·
Apr 20

BRIEF-Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due To Futility

Reuters
·
Apr 20

Arcus Biosciences Inc - Gilead's Option Rights Under Collaboration Agreement to End July 14, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 20

Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due to Futility - SEC Filing

THOMSON REUTERS
·
Apr 20